European Medicines Agency Updates Seasonal Flu Vaccine Guidance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Medicines Agency Updates Seasonal Flu Vaccine Guidance


The European Medicines Agency released an update to its guidance for the annual strain change of influenza vaccines to reflect current knowledge. The change makes the guidance document consistent with the approach taken by other global regulatory authorities. An improved system that allows strengthened and sustainable monitoring of an influenza vaccine’s performance over the years in a real-life setting is introduced in the guidance.

The guidance states that vaccine manufacturers will be required to submit for each vaccine appropriate measures for proactive surveillance of the safety and effectiveness to regulatory authorities for review. The requirement is for the influenza season 2014-2015 onwards. With the new system in place, EMA will no longer require routine submission of clinical trials for annual strain-change updates. An interim guidance will be published by March 2014 and will address the principles of safety monitoring commitments that should form part of the proactive surveillance.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here